Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Inogen, Inc.NASDAQ: INGN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $4.9M fell 5.5% year over year, behind the -2.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of -2.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 20.66M USD
- Year-over-year change
- -1.6%
- 4-year CAGR
- -1.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.66M | -1.6% |
| FY2024 | 2024-12-31 | 21M | +15.7% |
| FY2023 | 2023-12-31 | 18.15M | -22.8% |
| FY2022 | 2022-12-31 | 23.51M | +8.7% |
| FY2021 | 2021-12-31 | 21.63M | — |
Depreciation & Amortization vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 depreciation & amortization of $20.37M is the 3rd largest of the 11 companies compared; the peer median is $3.19M.
- Its year-over-year change of -2.6% is the 9th highest of 10, against a peer median of +35.4%.
- Depreciation & amortization amounts to 5.8% of revenue for INGN, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.3M | +18.5% | +1.5% | 16.6% | |
| LTM Mar 2026 | $22.58M | +148.0% | +52.4% | 15.6% | |
| LTM Mar 2026 | $20.37M | -2.6% | -4.2% | 5.8% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $3.67M | — | — | 6.8% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $2.74M | +63.9% | -5.7% | 2.3% | |
| LTM Mar 2026 | $690K | +3.1% | -11.8% | 0.9% | |
| LTM Mar 2026 | $672K | +1192.3% | +30.5% | 7.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $263.36K | +65.0% | +17.8% | — |
| LTM Mar 2026 | $103K | -90.0% | +10.5% | 0.2% | |
| Peer median (excluding INGN) | $3.19M | +35.4% | +10.5% | 7.0% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| Deferred Income Tax | 14.44M | 0 | (251K) | (1.15M) | (1.1M) |
| Stock-Based Compensation | 10.94M | 12.28M | 7.43M | 7.4M | 8.01M |
| Change in Working Capital | (20.07M) | (44.72M) | 14.27M | (4.39M) | (26.91M) |
| Accounts Receivables | (5.42M) | (51.62M) | 11.13M | (5.07M) | (14.62M) |
| Inventory | (10.78M) | (5.6M) | 7.88M | (3.54M) | (3.21M) |
| Accounts Payables | (6.48M) | 6.76M | (9.18M) | (3.41M) | 5.6M |
| Other Working Capital | 2.61M | 5.74M | 4.44M | 7.63M | (14.68M) |
| Other Non-Cash Items | 3.02M | 55.16M | 59.62M | 18.94M | 10.87M |
| Operating Cash Flow | 23.63M | (37.53M) | (3.23M) | 5.91M | (11.22M) |
| Capital Expenditures | (23.94M) | (21.22M) | (26.52M) | (17.09M) | (10.38M) |
| Acquisitions (Net) | 153K | 331K | (29.44M) | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (26.87M) | (32.66M) | (29.83M) |
| Sales of Investments | 19.26M | 10.01M | 24M | 35.5M | 14M |
| Other Investing Activities | 0 | 0 | 0 | (1.82M) | 0 |
| Investing Cash Flow | (14.65M) | (10.88M) | (59.32M) | (13.98M) | (26.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.65M | 1.74M | 1.48M | 811K | 28.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (647K) | (1.36M) | (518K) | (546K) | (4M) |
| Financing Cash Flow | 15M | 380K | 960K | 265K | 24.18M |
| Effect of Forex Changes | (426K) | (481K) | 67K | (281K) | 846K |
| Net Change in Cash | 23.56M | (48.51M) | (61.52M) | (8.08M) | (12.4M) |
| Free Cash Flow | (302K) | (58.75M) | (29.75M) | (11.18M) | (21.6M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.